ABIRATERONE ACETATE
us fda inspected manufacturing plantSAMPLES, WORKING STANDARDS AND IMPURITIES AVAILABLE
ABIRATERONE ACETATE (CAS 154229-19-3) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.
THERAPEUTIC INDICATION: ONCOLOGY
For the treatment of metastatic castration resistant prostate cancer.
MARKET INFORMATION
Originator: JOHNSON & JOHNSON
Originator product: ZYTIGA®
Core patent exclusivities : US 04/2015; Europe 09/2022
YOUR ADVANTAGES
- Manufactured in China
- API validated and commercially available
- US FDA-inspected manufacturing plant
- Samples, working standards and impurities are available
- Active US-DMF and ASMF available
This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.